Visual Impairment in Children with Epilepsy Treated with Vigabatrin
Ann Neurol 48:60-64, Gross-Tsur,V. et al, 2000
Vigabatrin-Associated Retinal Cone System Dysfunction, Electroretinogram & Ophthalmol Findings
Neurol 50:614-618, Krauss,G.L.,et al, 1998
Clemastine Fumarate as a Remyelinating Therapy for Multiple Sclerosis (ReBUILD): A Randomised, Controlled, Double-Blind, Crossover Trial
Lancet 390:2481-2489, Green, A.J.,et al, 2017
A Man Who Lost Weight and His Sight
Lancet 351:1174-1175, Moschos,M.&Droutsas,D., 1998
Intra-arterial Cisplatin-Associated Optic and Otic Toxicity
Arch Neurol 49:83-86, Maiese,K.,et al, 1992
Vision and Hearing During Deferoxamine Therapy
J Pediatr 117:326-330, Cohen,A.,et al, 1990
Disturbance of Cerebral Function by Aluminium in Haemodialysis Patients without Overt Aluminium Toxicity
Lancet 2:7-12, Altmann,P.,et al, 1989
Cortical Blindness:Etiology, Diagnosis, & Prognosis
Ann Neurol 21:149-158, Aldrich,M.S.,et al, 1987
Visual & Auditory Neurotoxicity in Patients Receiving Subcutaneous Deferoxamine Infusions
NEJM 314:869-873, Olivieri,N.F.,et al, 1986
Visual Evoked Potentials in the Detection of Subclinical Optic Toxic Effects Secondary to Ethambutol
Arch Neurol 40:645-648, Yiannikas,C.,et al, 1983
Toluene Optic Neuropathy
Ann Neurol 4:390, Keane,J.R., 1978